EUVIMEDEUVIMED entdecken
Crossref

Regulatory Effects of the PDE8B Inhibitor PF-04957325 on Cognitive Impairment and Neuroinflammation in Aβ-Induced Alzheimer’s Disease Mouse Models

YaQun Liu, MuYang Li, HongBo Yu, HuiYing Liu, QiuShuang Xu, Fang Li

Neurochemical Research · 2026

DOI: 10.1007/s11064-026-04830-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurochemical Research, 2026. Verfasst von YaQun Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jinzhou Medical University, Jinzhou, 121001, Liaoning, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Neuroinflammatory Diseases, Cognitive Dysfunction. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Medical Science Research Project of Hebei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) deposition, chronic neuroinflammation, and dysregulation of the cAMP/PKA/CREB pathway that impairs synaptic plasticity. PF-04957325 (PF), a selective PDE8B inhibitor, elevates intracellular cAMP; however, its systems-level effects and mechanisms in Aβ-driven AD are unclear. Here, we evaluate PF in an Aβ1-42 mouse model and delineate its modulation of cAMP/PKA/CREB and TLR4/MyD88/NF-κB signaling. An AD model was induced by intracerebroventricular injection of Aβ1-42, followed by oral PF administration (0.1 mg/kg/day). Cognitive performance was evaluated with the Morris water maze. Hippocampal pathology, Aβ burden, and apoptosis were assessed by H&E, immunohistochemistry, and TUNEL assays. IL-1β and IL-6 were measured by ELISA in hippocampal tissue and BV2 supernatants. Western blotting quantified APP, p-tau, and pathway proteins. BV2 cells and si-PDE8B served to validate mechanisms in vitro. PF significantly shortened escape latency (p < 0.01) and increased both platform crossings and target-quadrant dwell time (p < 0.01). It alleviated hippocampal neuronal injury, reduced Aβ burden, and decreased TUNEL-positive cells. Molecularly, PF elevated cAMP and increased p-PKA/PKA and p-CREB/CREB ratios (p < 0.01), while decreasing TLR4, MyD88, and p-NF-κB p65/NF-κB p65 (p < 0.01). PF also lowered IL-1β and IL-6 levels in hippocampal tissue and BV2 supernatants (both p < 0.01). In vitro, 300 nM PF phenocopied PDE8B knockdown, restoring cAMP/PKA/CREB activity and suppressing TLR4/MyD88/NF-κB activation. PF exerts dual protective effects by activating cAMP/PKA/CREB to enhance synaptic plasticity and survival, while inhibiting TLR4/MyD88/NF-κB to mitigate neuroinflammation. These findings highlight PDE8B inhibition as a promising therapeutic strategy for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesNeuroinflammatory DiseasesCognitive DysfunctionAnimalsMaleMicePeptide FragmentsDisease Models, AnimalHippocampusSignal TransductionMice, Inbred C57BLMaze LearningCyclic AMP Response Element-Binding ProteinMyeloid Differentiation Factor 88Toll-Like Receptor 4NF-kappa B

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid-βCognitive impairmentNeuroinflammationPF-04957325cAMP/PKA/CREB pathway

Substanzen

Amyloid beta-PeptidesPeptide FragmentsCyclic AMP Response Element-Binding ProteinMyeloid Differentiation Factor 88Toll-Like Receptor 4amyloid beta-protein (1-42)NF-kappa B

Autor:innen und Institutionen

  • Jinzhou Medical University, Jinzhou, 121001, Liaoning, China.
  • Department of Neurology, Peking University Third Hospital Qinhuangdao Hospital, Qinhuangdao, 066001, Hebei, China.
  • Department of Neurovascular Interventional, Peking University Third Hospital Qinhuangdao Hospital, Qinhuangdao, 066001, Hebei, China.
  • Department of Cardiovascular Medicine II, Qinhuangdao Hospital of Dongfang Hospital, Beijing University of Chinese Medicine, Qinhuangdao, 066000, Hebei, China.
  • Department of Neurology, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Jinzhou, 121001, Liaoning, China. lifangyaiii@hotmail.com.

Förderung

  • Medical Science Research Project of Hebei

Zitieren

APA

Liu, Y., Li, M., Yu, H., Liu, H., Xu, Q., & Li, F. (2026). Regulatory Effects of the PDE8B Inhibitor PF-04957325 on Cognitive Impairment and Neuroinflammation in Aβ-Induced Alzheimer’s Disease Mouse Models. Neurochemical Research. https://doi.org/10.1007/s11064-026-04830-7

Vancouver

Liu Y, Li M, Yu H, Liu H, Xu Q, Li F. Regulatory Effects of the PDE8B Inhibitor PF-04957325 on Cognitive Impairment and Neuroinflammation in Aβ-Induced Alzheimer’s Disease Mouse Models. Neurochemical Research. 2026. doi:10.1007/s11064-026-04830-7

BibTeX
@article{Liu2026,
  author = {Liu, YaQun and Li, MuYang and Yu, HongBo and Liu, HuiYing and Xu, QiuShuang and Li, Fang},
  title = {Regulatory Effects of the PDE8B Inhibitor PF-04957325 on Cognitive Impairment and Neuroinflammation in Aβ-Induced Alzheimer’s Disease Mouse Models},
  journal = {Neurochemical Research},
  year = {2026},
  doi = {10.1007/s11064-026-04830-7}
}
Kostenlos starten →